Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nicole Williams

Gynecology Chicago, IL Medical Doctor

NPI 1164441051 CMS profile 279835

680 N Lake Shore Dr Ste 1424, Suite 200, Chicago, IL 60611

Open in the dashboard

General payments

$527,343

944 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicole Williams of Chicago, IL is reported in the CMS Open Payments database as having received $527,343 across 944 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,964 45
2024 General $34,664 85
2023 General $138,657 189
2022 General $190,294 258
2021 General $96,736 197
2020 General $16,693 66
2019 General $33,335 104

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Williams
  • Gynecology median
  • Middle half of Gynecology
  • National median

In program year 2025, general payments to Nicole Williams were reported at $16,964. Among 1,279 Gynecology profiles paid that year, the median was $162 and the middle half received between $56 and $501.

Show as a table
Year Nicole Williams Gynecology median Middle half National median
2019 $33,335 $199 $66–$472 $163
2020 $16,693 $114 $42–$287 $114
2021 $96,736 $141 $42–$430 $132
2022 $190,294 $173 $52–$532 $149
2023 $138,657 $170 $57–$501 $160
2024 $34,664 $157 $50–$424 $164
2025 $16,964 $162 $56–$501 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Acessa Health Inc. $319,881 295 payments
  2. Myovant Sciences Inc. $55,516 49 payments
  3. AbbVie, Inc. $35,333 82 payments
  4. Acessa Health Inc. $29,107 43 payments
  5. Sumitomo Pharma America, Inc. $27,405 45 payments
  6. Hologic, LLC $26,051 125 payments
  7. Astellas Pharma US Inc $11,058 20 payments
  8. Intuitive Surgical, Inc. $8,758 15 payments
  9. Pfizer Inc. $3,528 6 payments
  10. Coloplast Corp $2,349 25 payments
  11. Other $8,356 239 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $297,643 86 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $117,163 53 payments
  3. Travel and Lodging $86,966 318 payments
  4. Food and Beverage $17,921 475 payments
  5. Education $7,620 10 payments
  6. Gift $30 2 payments
Products named General payments · program years 2019–2025
  1. ACESSA PROVU SYSTEM Surgical $271,684 290 payments
  2. MYFEMBREE Hormone Therapy $82,922 94 payments
  3. ACESSA PROVU SYSTEM Surgical $71,402 107 payments
  4. Acessa $29,107 43 payments
  5. ORIAHNN $25,715 49 payments
  6. Veozah $10,487 16 payments
  7. Da Vinci Surgical System $8,758 15 payments
  8. ORILISSA $6,412 46 payments
  9. MYFEMBREE Genitourinary (Sexual Health);Womens Health $3,528 6 payments
  10. Endometrial Ablation System (Device) $1,695 4 payments
  11. Other $11,183 322 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

45

Median for Obstetrics & Gynecology: 65

Drug cost

$19,012

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

51.1%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myfembree Relugolix/Estradiol/Norethindr Brand 11 $14,303
Prempro Estrogen,con/M-Progest Acet Brand 12 $2,761
Estradiol Generic 22 $1,948

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$10,893

Medicare's payments for the services billed

Medicare patients

49

Average age 69

Services billed

109

49 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 53%
Arthritis 47%
Depression 24%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $5,446
$5,446 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $207
  • PFIZER INC. $43
$250 11 —
SLYND
  • Exeltis, USA Inc. $43
$43 — —
PREMARIN
  • PFIZER INC. $43
$43 — —
Wegovy
  • Novo Nordisk Inc $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

944 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record